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Brain abscesses are a challenging emergency and any delay in diagnosis or treatment may result in poor health outcomes 
for affected patients. The incidence of this infectious 
disease is approximately 0.4–0.9 per 100,000 
individuals worldwide, with much higher rates among 
immunocompromised patients.1 Brain abscesses can 
be caused by bacteria, fungi or parasites.1 Aspergillus sp. 
is an opportunistic ubiquitous fungus that usually 
enters the body by inhalation of airborne spores; it can 
then invade the central nervous system (CNS) via the 
haematogenous route, from direct extension through 
the paranasal sinuses or by direct inoculation during 
trauma or surgical procedures.2,3 Invasive intracranial 
aspergillosis is unusual, accounting for 10–20% of all 
cases of invasive aspergillosis.4 Most patients with this 
condition have immune defects, usually in the form of 
neutrophil or macrophage dysfunction.5,6 
Invasive intracranial aspergillosis is associated 
with high morbidity and mortality rates; the latter 
can be as high as 88% in bone marrow transplant 
recipients and for those with disseminated or 
cerebral aspergillosis.2,7,8 CNS-invasive aspergillosis 
may present with meningitis, cerebritis, infarctions, 
abscesses, granulomas or mycotic aneurysms.9 The 
exact pathology depends upon the disease pathway and 
the host’s immunity. The most frequent pathological 
findings are haemorrhage, infarctions and abscesses.10 
Rarely, Aspergillus infections present as space-
occupying lesions in immunocompetent patients.3,10 
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abstract: Intracranial aspergillosis is an extremely rare manifestation of invasive aspergillosis in immuno-
competent children and is associated with high morbidity and mortality. We report a 12-year-old immunocompetent 
male child who was referred to the King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, in May 
2010 after a sudden-onset headache and loss of consciousness. Brain imaging revealed a large right space-occupying 
occipital lesion and the patient underwent a craniotomy and resection. Histopathology of the lesion revealed 
necrotising granulomatous fungal encephalitis with many hyphae engulfed by multinucleated giant histiocytes. 
Two days later, a computed tomography scan showed debulking of the fungal mass and the patient was discharged 
on oral voriconazole. However, imaging at a six-week follow-up showed progression of the abnormality. A residual 
or persistent fungal brain lesion was suspected. Further neurosurgical resection of the lesion was performed and 
cultures showed growth of Aspergillus flavus. The patient was treated successfully with antifungal therapy over the 
following two years.
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املناعية وتكون  الكفاءة  الأطفال ذوي  الجتياحية يف  الر�سا�سيات  للغاية من  نادر  الدماغي مظهر  القحف  الر�سا�سيات داخل  امللخ�ص: 
اإىل م�ست�سفى امللك في�سل التخ�س�سي  اأحيل  12 عاما  معدلت العتالل والوفيات نتيجة لذلك مرتفعة. نفيدكم باأن طفل بالغ من العمر 
ومركز الأبحاث يف مايو 2010 حيث اأن املري�س اأ�سيب ب�سداع مفاجئ وفقدان للوعي. ك�سف ت�سوير الدماغ الأمين اآفة قذايل حتتل م�ساحة 
العديد من  مع  تقرحي  دماغ فطري حبيبي  التهاب  بوجود  امل�ستاأ�سل  الن�سيج  درا�سة  وك�سفت  الآفة.  املري�س ل�ستئ�سال  كبرية وخ�سع 
اخليوط املحاطة مبن�سجات عمالقة متعددة النوى. بعد يومني، اأظهر امل�سح املقطعي املحو�سب خلو املخ من الكتلة الفطرية وخرج املري�س 
على دواء فوريكونازول. ومع ذلك، اأظهر الت�سوير املغناطي�سي خالل �ستة اأ�سابيع تطور الفطريات يف الدماغ مرة اأخرى. مت تنفيذ مزيد من 
البرت لالآفة يف جراحة الأع�ساب واأظهرت زارعة الن�سجه منو فطريات الفالف�س.ومت عالج املري�س بنجاح بالأدوية امل�سادة للفطريات 
على مدى العامني التاليني.
كلمات مفتاحية: خراج الدماغ؛ الأمرا�س الفطرية؛ ار�سا�سيات فالف�س؛ الأدوية امل�سادة للفطريات؛ الكفاءة املناعية؛ تقرير حالة؛ العربية ال�سعودية.
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were requested as the lesion was believed to be a 
tumour. The patient was prescribed daily intravenous 
liposomal amphotericin B (5 mg/kg/dose). Two days 
after the surgery, a brain CT scan showed debulking 
of the right-sided occipital fungal mass. The extent 
of the perilesional reactive changes had regressed 
with a persistent mild midline shift to the left and 
regression of the right trigone effacement [Figure 1B]. 
Blood assays showed high (1,3)-beta-D-glucan levels 
(272 picogrammes [pg]/mL; normal range: 0‒60 pg/mL) 
and non-reactive Aspergillus galactomannan. An eye 
examination, abdominal ultrasound and echocar-
diogram were unremarkable. The results of an immun- 
ological work-up were normal, including serum 
immunoglobulin levels, lymphocyte markers, blasto-
genic response, complement deficiency, oxida-tive 
burst and polymorphonuclear chemotaxis. A human 
immunodeficiency virus infection test was negative. 
The patient was discharged on oral voriconazole 
(6 mg/kg every 12 hours).
At a six-week follow-up appointment, the patient 
underwent CT and MRI scans of the brain which 
showed a progression of the dense solid marginal tissue 
abnormality. The enhancement was consistent with 
a granulomatous tissue abnormality [Figure 2A]. A 
residual or persistent fungal brain lesion was suspected 
and the patient subsequently underwent surgical 
exploration with further resection of the lesion. The 
histopathology remained consistent with that of the 
first resected brain lesion; however, cultures showed A. 
flavus growth. Oral administration of voriconazole was 
substituted for intravenous administration (6 mg/kg 
every 12 hours). Two days later, a postoperative CT 
scan showed a slight nonspecific enhancement in 
the periphery of the resected area. The patient was 
discharged with a prescription for oral voriconazole 
(6 mg/kg every 12 hours).
This report describes an invasive Aspergillus-induced 
brain abscess in an immunocompetent patient with no 
history of trauma. 
Case Report
A previously healthy 12-year-old male child was 
referred to the King Faisal Specialist Hospital & 
Research Centre, Riyadh, Saudi Arabia, in May 
2010 after a sudden-onset headache and loss of 
consciousness for 15 minutes. He had no convulsions, 
abnormal movements, eye abnormalities, vision 
impairment, fever, vomiting or skin rashes. In addition, 
he had no history of trauma. On examination, the 
patient was stable and interactive with no obvious 
neurological deficits. Computed tomography (CT) 
of the brain showed a right occipital space-occupying 
lesion, suspected to be a tumour. The nasal sinuses 
were clear. His complete blood count (haemoglobin: 
135 g/L; white blood cell count: 6.4 x 109/L; neutrophil 
count: 2.51 x 109/L; eosinophils: 0.47 x 109/L; platelet 
count: 333 x 109/L) and erythrocyte sedimentation 
rate (3 mm/hour) were normal. Magnetic resonance 
imaging (MRI) of the brain revealed a large right 
occipital mass with heterogeneous enhancement and 
perifocal oedema in the right temporal and parietal 
lobes. The right occipital horn was compressed and 
there was a midline shift to the left [Figure 1A]. A 
preoperative diagnosis of a brain tumour was made.
The patient underwent a craniotomy and resection 
of the brain lesion. Histopathology examination 
of the lesion revealed necrotising granulomatous 
fungal encephalitis with many hyphae engulfed 
by multinucleated giant histiocytes. No cultures 
 
Figure 1A&B: A: Magnetic resonance imaging of 
the brain of a 12-year-old immunocompetent child 
showing a large right occipital mass (arrow) with 
heterogeneous enhancement, perifocal oedema in the 
right temporal and parietal lobes and a midline shift to 
the left. The nasal sinuses were clear. B: Post-resection 
computed tomography showing debulking of the right-
sided occipital fungal mass (arrow) two days later. Note 
the regression of the perilesional reactive changes with 
a persistent mild midline shift to the left and regression 
of the right trigone effacement. 
 
Figure 2A&B: A: Magnetic resonance imaging (MRI) of 
the brain of a 12-year-old immunocompetent child six 
weeks after an initial resection of a right occipital fungal 
mass showing progression of the dense solid marginal 
tissue abnormality (arrow) and enhancement consistent 
with a granulomatous tissue abnormality. B: Brain MRI 
one month after the second resection showing partial 
resolution of the solid parenchymal abnormality (arrow). 
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In the current case, the patient had invasive CNS 
aspergillosis without paranasal sinus involvement and 
with no identifiable immune defects. Although he had 
negative Aspergillus serum galactomannan antigens, 
this negative result does not exclude a diagnosis 
of invasive aspergillosis.13 Culture supernatants of 
A. flavus have demonstrated lower reactivity, with 
lower galactomannan concentrations.14 Negative 
results could be due to factors related to the host, 
the assay or the fungus itself. One of the blood 
investigations which can be used to detect Aspergillus 
is the enzyme-linked immunosorbent assay Platelia™ 
Aspergillus EIA (Bio-Rad Laboratories, California, 
USA); this assay is most favourable in patients with 
haematological malignancies, especially those who 
have undergone a haematopoietic stem cell transplant 
and are neutropaenic.15 
It is not clear how the patient in the present case 
developed the brain abscess. Although no immune 
defects were identified, he may nevertheless have been 
suffering from a rare form of immunodeficiency, such 
as an interleukin (IL)-4 or IL-6 deficiency; suppression 
of monocytes and T helper cells and interferon-gamma 
(IFN-γ) responses can lead to severe Aspergillus 
infections.13,16 A previous case report has indicated 
the beneficial role of IFN-γ treatment in combination 
with antifungal drugs in managing a patient with an 
A. fumigatus-induced brain abscess.17
Conclusion
Persistent cerebral Aspergillus-induced abscesses in 
immunocompetent patients are extremely rare and 
the clinical and radiological features of these cases 
may be similar to primary or secondary neoplasms or 
other forms of infection. Health professionals should 
therefore be aware of the symptoms of Aspergillus-
induced brain abscesses, as early detection and 
appropriate treatment is necessary to ensure positive 
patient outcomes.
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